Open Access

ARTICLE

MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes

Hong Truong^1,*, Jennifer Logan^1,*, Baris Turkbey², M. Minhaj Siddiqui¹, Soroush Rais-Bahrami¹, Anthony N. Hoang¹, Chad Pusateri¹, Brian Shuch¹, Annerleim Walton-Diaz¹, Srinivas Vourganti¹, Jeffrey Nix¹, Lambros Stamatakis¹, Colette Harris¹, Celene Chua¹, Peter L. Choyke², Bradford J. Wood³, Peter A. Pinto^1,3

1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
3 Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Address correspondence to Dr. Peter A. Pinto, Urologic Oncology Branch,National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1210, Building 10, CRC Room 2W-5940 , Bethesda, MD 20892-1210 USA

Canadian Journal of Urology 2013, 20(6), 7002-7007.

Abstract

Introduction: Prior studies of volumetric effects of 5α-reductase inhibitors (5ARIs) on the prostate have used transrectal ultrasound which provides poor differentiation of prostatic zones. We utilized high-resolution prostate MRI to evaluate the true dynamic effects of 5ARI in men who underwent multiple MRIs.
Materials and methods: A retrospective study of patients who underwent serial 3.0 Tesla prostate MRI from 2007 to 2012 and were treated with 5ARI were studied. Nineteen patients who had a baseline MRI prior to 5ARI initiation and subsequent MRI follow up were selected. A randomly selected group of 40 patients who had not received any form of therapy was selected as the control cohort. Total prostate volume (TPV), transition zone volume (TZV), and peripheral zone volume (PZV) were calculated using 3D reconstructions and prostate segmentation from T2-weighted MRI. Changes in volumes were correlated with the duration of treatment using linear regression analysis.
Results: Following over 2 years of treatment, 5ARI decreased TPV significantly (16.7%, p < 0.0001). There were similar decreases in TZV (7.5%, p < 0.001) and PZV (27.4%, p = 0.0002) from baseline. In the control group, TPV and TZV increased (p < 0.0001) while PZV remained stable. When adjusted for the natural growth of prostate zonal volume dynamics seen in the control cohort, approximately 60% of the reduction of the TPV from 5ARI resulted from changes in the TZV and 40% of the reduction from changes in the PZV.
Conclusions: 3.0 Tesla MRI characterizations of the dynamic effects of 5ARI on prostate zonal volumes demonstrate significant decreases in TPV, TZV, and PZV. 5ARI blocks the natural growth of TZV as men age and decreases both TZV and PZV below their baselines. As imaging technology improves, prostate MRI allows for more accurate assessment of drug effects on dynamic prostate volumes.

---

Keywords

---